Raza M Alvi1, Markella V Zanni2, Anne M Neilan3, Malek Z O Hassan1, Noor Tariq4, Lili Zhang1, Maryam Afshar5, Dahlia Banerji1, Connor P Mulligan1, Adam Rokicki1, Magid Awadalla1, James L Januzzi6, Tomas G Neilan1. 1. Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2. Metabolism Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. 3. Division of Infectious Diseases, Department of Medicine and Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 4. Yale-New Haven Hospital of Yale University School of Medicine, New Haven, Connecticut, USA. 5. Bronx-Lebanon Hospital Center of Icahn School of Medicine at Mount Sinai, Bronx, New York. 6. Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Among persons living with human immunodeficiency virus (PHIV), incident heart failure (HF) rates are increased and outcomes are worse; however, the role of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations among PHIV with HF has not been characterized. METHODS: Patients were derived from a registry of those hospitalized with HF at an academic center in a calender year. We compared the NT-proBNP concentrations and the changes in NT-proBNP levels between PHIV with HF and uninfected controls with HF. RESULTS: Among 2578 patients with HF, there were 434 PHIV; 90% were prescribed antiretroviral therapy and 62% were virally suppressed. As compared to controls, PHIV had higher admission (3822 [IQR, 2413-7784] pg/ml vs 5546 [IQR, 3257-8792] pg/ml, respectively; P < .001), higher discharge (1922 [IQR, 1045-4652] pg/ml vs 3372 [IQR, 1553-5452] pg/ml, respectively; P < .001), and lower admission-to-discharge changes in NT-proBNP levels (32 vs 48%, respectively; P = .007). Similar findings were noted after stratifying based on left ventricular ejection fraction (LVEF). In a multivariate analysis, cocaine use, a lower LVEF, a higher NYHA class, a higher viral load (VL), and a lower CD4 count were associated with higher NT-proBNP concentrations. In follow-up, among PHIV, a higher admission NT-proBNP concentration was associated with increased cardiovascular mortality (first tertile, 11.5; second tertile, 20; third tertile, 44%; P < .001). Among PHIV, each doubling of NT-proBNP was associated with a 19% increased risk of death. However, among patients living without HIV, each doubling was associated with a 27% increased risk; this difference was attenuated among PHIV with lower VLs and higher CD4 counts. CONCLUSIONS: PHIV with HF had higher admission and discharge NT-proBNP levels, and less change in NT-proBNP concentrations. Among PHIV, VLs and CD4 counts were associated with NT-proBNP concentrations; in follow-up, higher NT-proBNP levels among PHIV were associated with cardiovascular mortality.
BACKGROUND: Among persons living with human immunodeficiency virus (PHIV), incident heart failure (HF) rates are increased and outcomes are worse; however, the role of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations among PHIV with HF has not been characterized. METHODS:Patients were derived from a registry of those hospitalized with HF at an academic center in a calender year. We compared the NT-proBNP concentrations and the changes in NT-proBNP levels between PHIV with HF and uninfected controls with HF. RESULTS: Among 2578 patients with HF, there were 434 PHIV; 90% were prescribed antiretroviral therapy and 62% were virally suppressed. As compared to controls, PHIV had higher admission (3822 [IQR, 2413-7784] pg/ml vs 5546 [IQR, 3257-8792] pg/ml, respectively; P < .001), higher discharge (1922 [IQR, 1045-4652] pg/ml vs 3372 [IQR, 1553-5452] pg/ml, respectively; P < .001), and lower admission-to-discharge changes in NT-proBNP levels (32 vs 48%, respectively; P = .007). Similar findings were noted after stratifying based on left ventricular ejection fraction (LVEF). In a multivariate analysis, cocaine use, a lower LVEF, a higher NYHA class, a higher viral load (VL), and a lower CD4 count were associated with higher NT-proBNP concentrations. In follow-up, among PHIV, a higher admission NT-proBNP concentration was associated with increased cardiovascular mortality (first tertile, 11.5; second tertile, 20; third tertile, 44%; P < .001). Among PHIV, each doubling of NT-proBNP was associated with a 19% increased risk of death. However, among patients living without HIV, each doubling was associated with a 27% increased risk; this difference was attenuated among PHIV with lower VLs and higher CD4 counts. CONCLUSIONS: PHIV with HF had higher admission and discharge NT-proBNP levels, and less change in NT-proBNP concentrations. Among PHIV, VLs and CD4 counts were associated with NT-proBNP concentrations; in follow-up, higher NT-proBNP levels among PHIV were associated with cardiovascular mortality.
Authors: Aditya Bhonsale; Cynthia A James; Crystal Tichnell; Brittney Murray; Dmitri Gagarin; Binu Philips; Darshan Dalal; Ryan Tedford; Stuart D Russell; Theodore Abraham; Harikrishna Tandri; Daniel P Judge; Hugh Calkins Journal: J Am Coll Cardiol Date: 2011-09-27 Impact factor: 24.094
Authors: Adeel A Butt; Chung-Chou Chang; Lewis Kuller; Matthew Bidwell Goetz; David Leaf; David Rimland; Cynthia L Gibert; Krisann K Oursler; Maria C Rodriguez-Barradas; Joseph Lim; Lewis E Kazis; Stephen Gottlieb; Amy C Justice; Matthew S Freiberg Journal: Arch Intern Med Date: 2011-04-25
Authors: Raza M Alvi; Anne M Neilan; Noor Tariq; Malek O Hassan; Magid Awadalla; Lili Zhang; Maryam Afshar; Adam Rokicki; Connor P Mulligan; Virginia A Triant; Markella V Zanni; Tomas G Neilan Journal: JACC Heart Fail Date: 2019-08-07 Impact factor: 12.035
Authors: David B Hanna; Uriel R Felsen; Mindy S Ginsberg; Barry S Zingman; Robert S Beil; Donna C Futterman; Howard D Strickler; Kathryn Anastos Journal: AIDS Res Hum Retroviruses Date: 2016-03-17 Impact factor: 2.205
Authors: Eric A Secemsky; Rebecca Scherzer; Elaine Nitta; Alan H B Wu; David C Lange; Steven G Deeks; Jeffrey N Martin; James Snider; Peter Ganz; Priscilla Y Hsue Journal: JACC Heart Fail Date: 2015-07-08 Impact factor: 12.035
Authors: Shane A Perrine; Raghavendra Nayak; Aditya S Bharadwaj; George McKelvey; Tamam Mohamad; Sony Jacob Journal: Pacing Clin Electrophysiol Date: 2010-10-14 Impact factor: 1.976
Authors: Thomas J Wang; Kai C Wollert; Martin G Larson; Erin Coglianese; Elizabeth L McCabe; Susan Cheng; Jennifer E Ho; Michael G Fradley; Anahita Ghorbani; Vanessa Xanthakis; Tibor Kempf; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan; James L Januzzi Journal: Circulation Date: 2012-08-20 Impact factor: 29.690
Authors: Daniel A Duprez; Jacqueline Neuhaus; Russell Tracy; Lewis H Kuller; Steven G Deeks; Chloe Orkin; Albrecht Stoehr; Ian J Woolley; James D Neaton Journal: AIDS Date: 2011-03-13 Impact factor: 4.177